Home – Page 11 – The Cancer Letter

Issue 19 - May 8, 2020

TCL46-19 (816 downloads)

Guest Editorial
COVID-19 and community cancer care
A panorama of a catastrophe
The COVID-19 pandemic has been catastrophic to health care in the US.
Much has been written about the impact on hospitals and on the health care professionals enduring horrific stress to support the acutely ill. These providers are heroes, and we are all indebted to them. But less attention has been paid to the indirect effects of the pandemic on health care, particularly the care delivered to those with chronic medical illnesses.
NCI receives $306 million in new money for COVID-19 serology test research;
Details to follow at BSA meeting May 12
NCI has received additional $306 million under a COVID-19 aid package “to develop, validate, improve, and implement serological testing and associated technologies applicable to COVID-19.”
Fox Chase will not be sold to Jefferson after all
Deal becomes a “casualty of COVID-19”
The deal is off: Fox Chase Cancer Center will not be sold to Thomas Jefferson University.
COVID-19 slams into the nation’s capital region;
Here is the damage assessment at six institutions
In the first effort of its sort, The Cancer Letter has compiled a damage assessment, gauging the severity of the COVID-19 outbreak in the District of Columbia, Maryland and Virginia, gathering information on populations that were struck hardest, and quantifying impact on academic cancer centers and large hospital systems.
Conversation with The Cancer Letter
Lessons from COVID-19:
Leaders of six cancer centers in the DMV area tell us about caseloads, the outlook—and impact
As the District of Columbia, Maryland, and Virginia prepare to loosen pandemic restrictions and reopen economies, hospital networks and academic cancer centers brace for a potential uptick in SARS-CoV-2 infections.
An Appreciation
Paul A. Marks, architect of modern academic oncology who led MSK for two decades, dies at 93
On rare occasion, an innovator makes such a profound impact on the world that people thereafter cannot imagine what life was like before that transformation. Paradoxically, for those not witness to such an achievement, this phenomenon may have, in terms of legacy, a blunting effect.
Guest Editorial
Embracing the increasing value of eHealth in patient-centered cancer care during the COVID-19 pandemic and beyond
In the past decade, there has been a growing interest in capitalizing on advances in information technology to provide quality and patient-centered care to cancer patients and survivors outside a hospital or clinic setting.
Guest Editorial
With the COVID-19 pandemic, the cancer clinical trials—they are a-changing
Prior to the COVID-19 pandemic, NCI estimated that about 3% to 5% of adult cancer patients participated in clinical trials.
COVID-19 Updates
- Democratic senators call for $26B in next COVID-19 relief package to support research workforce
- House members call for equal access to affordable oral chemotherapy prescription drugs amidst COVID-19 outbreak
In Brief
- Patton named CEO of OneOncology
- Blumenthal named VP of Global Oncology Regulatory Affairs at Merck
- Haura, Khushalani named clinical science research leaders at Moffitt
- Bona named director of Benign Hematology at Smilow Cancer Hospital
- Prebet, Zeidan named hematology leaders at Yale Cancer Center
- Hamilton, Danilov join City of Hope
- Tempera named associate professor in the Gene Expression & Regulation Program at Wistar
- Bin Tian appointed professor, co-director of the Center for Systems & Computational Biology at Wistar
- Tsvi Gal named head of infrastructure at MSK
- Seattle Cancer Care Alliance opens Acute Clinical Evaluation Clinic
- Robert Peter Gale receives ASJA award for “Chernobyl, the HBO miniseries: Fact and Fiction”
Clinical Roundup
- Cancer patients without insurance or Medicaid don’t experience the same benefits of clinical trials
- Libtayo shows clinically-meaningful and durable responses in second-line advanced basal cell carcinoma
- New tumor sampling method significantly improves genetic testing for cancer treatment
Drugs & Targets
- FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC
- FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
- FDA accepts NDA for CC-486 in AML indication
- Caris Life Sciences submits two PMA applications to FDA for whole exome and whole transcriptome sequencing
NCI Trials
NCI Trials for May 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 18 - May 1, 2020

TCL46-18 (775 downloads)

Real-World Evidence
COVID-19 vs. community oncology: Flatiron’s data provides first damage assessment
Community oncology practices in the United States are reeling from a sharp decrease in business—whether you look at new patients, chemotherapy visits, or non-chemo visits—the result of reduced activity and stay-at-home orders across the country to mitigate the spread of SARS-CoV-2.
Conversation with The Cancer Letter
NSCLC patients getting checkpoint inhibitors more likely to develop pneumonitis, Syapse-FDA-Aurora study finds
Patients with lung cancer and a history of pneumonitis are more likely to develop treatment-associated pneumonitis later, especially in the course of receiving immune checkpoint inhibitor therapy, according to a new study by Syapse, FDA, and Advocate Aurora Health.
Conversation with The Cancer Letter
Skip Burris: These few months are going to shape health care in the coming years
The COVID-19 pandemic will change the structure and economics of clinical care and clinical trials in cancer, said Howard “Skip” Burris, president of clinical operations and chief medical officer of Sarah Cannon, the Cancer Institute of HCA Healthcare.
AACR data from China and Europe amount to “two different messages” for cancer patients with COVID-19
Are COVID-19 patients with cancer at a greater risk of dying than non-cancer patients? Depends on whom you ask.
Conversation with The Cancer Letter
With 61,000 people registered, first-ever virtual AACR annual meeting “enthusiastically received”
Nobody knew how to even begin to predict the number of people who would register for the first-ever virtual annual meeting of the American Association for Cancer Research.
Remdesivir established as standard of care for COVID-19, Fauci declares
FDA issues Emergency Use Authorization
Early data from two randomized phase III studies of the antiviral drug remdesivir make it a viable treatment for COVID-19.
Guest Editorial
Under the onslaughts of COVID-19, Montefiore deployed a PPE strategy for patients—PREVENT/PROTECT/ENABLE
March 1, 2020, started as a good day at the Montefiore Einstein Center for Cancer Care in New York.
Guest Editorial
The pandemic of COVID-19 and its effect on clinical trials in the community
How do we move forward?
This pandemic has affected a lot of people, both physicians and patients, physically as well as emotionally.
Guest Editorial
Cancer doesn’t wait—we are treating cancer patients now
As part of responding to the COVID-19 pandemic, hospitals across the nation had dramatically reduced their surgery schedules when UC Davis cancer patient Marlene Blake had surgery for breast cancer in March.
Dafna Bar-Sagi, Arul Chinnaiyan, Carl June, Christopher Lima, Miriam Merad, and John Schiller are among newly elected NAS members
The National Academy of Sciences announced the election of 120 members and 26 international members in recognition of their distinguished and continuing achievements in original research.
Covid-19 Updates
- FDA grants Emergency Use Authorization for novel, non-implanted device to wean patients off mechanical ventilation
- TGen seeks volunteers for COVID-19 immunity study
- J&J and Emergent Bio collaborate on coronavirus vaccine candidate
In Brief
- Kristin Brill named enterprise director of Breast Oncology at SKCC
- UCLA researchers receive $2.8M NCI grant to develop blood-based test for liver transplant candidate selection
- 2020 Stovall award nominations due May 1
Clinical Roundup
- Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvement
- Lynparza demonstrates OS benefit in phase III prostate cancer trial
- GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer
- MD Anderson, Ipsen advance therapy with potential benefit for patients with lung, ovarian cancer
- Study: Disruptions in health insurance coverage are common, and affect cancer care and survival
- AI may help brain cancer patients avoid biopsy
- Mouse model study shows promise in treatment of medulloblastoma and ependymoma
Drugs & Targets
- FDA approves GSK’s PARP inhibitor Zejula for first-line maintenance of advanced ovarian cancer
- FDA grants accelerated approval to new dosing regimen for Keytruda
- FDA grants Mobocertinib Breakthrough Therapy Designation in NSCLC designation
Clarification

Issue 17 - Apr 24, 2020

TCL46-17 (855 downloads)

Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19
Phase III results for remdesivir expected within weeks
Experts in infectious diseases and investors on Wall Street are honing in on two potential treatments for COVID-19: interleukin inhibitors and remdesivir.
Conversation with The Cancer Letter
Berry: “Designing clinical trials doesn’t have high priority when there’s no pandemic. And then, when there’s a pandemic, there’s panic”
After a series of global epidemics, Don Berry has spent the past several years preparing for a serious pandemic that would be caused by yet another viral pathogen.
Guest Editorial
When disparities widen: COVID-19 in minority patients with cancer
In late December, rumors regarding a dangerous virus that originated in a seafood market in Wuhan, China started spreading across the world. At the time, all we knew was that the virus resembled the severe acute respiratory syndrome, better known as SARS, and that it was aggressive and deadly.
Guest Editorial
COVID-Lung Cancer Consortium:
An example of how the lung cancer community came together in challenging times
The COVID-19 pandemic has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and health care providers.
Conversation with The Cancer Letter
Feist-Weiller mammography vans repurposed to screen for COVID-19 in northwest Louisiana
At least for now, Feist-Weiller Cancer Center at the Louisiana State University Health Sciences Center at Shreveport has repurposed the three vans that were used to provide cancer screening and essential health care to medically underserved communities.
Conversation with The Cancer Letter
Tulane Cancer Center chips away at the “digital divide” that keeps the underserved from benefiting from telemedicine
In the past, few patients had Oliver Sartor’s personal cell phone number.
Since the COVID-19 outbreak in New Orleans, Sartor, professor of medicine and medical director of Tulane Cancer Center, C.E. and Bernadine Laborde Professor of Cancer Research, gives out his number to all patients as part of telehealth visits.
Conversation with The Cancer Letter
As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening
News coverage of the COVID-19 pandemic in New York has lent urgency to social distancing efforts in San Antonio and South Texas, likely flattening the curve.
COVID-19 Updates
- FDA issues advisory on off-label use of hydroxychloroquine and chloroquine
- AACI annual meeting goes virtual
- Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE
- Western NY researchers study COVID-19 using NGS to identify immune response biomarkers
- Invitae develops tools to support telemedicine
- Kennedy, former FDA commissioner and Stanford president, dies of COVID-19
- FAQs and Guidances
In Brief
- ASCO announces 2020 awards
- Serody and Basch named to leadership roles at UNC
- Poynter, Harki appointed to leadership team at Masonic Cancer Center
- American Heart Association grants $17 million for studies on health impact of e-cigarettes and nicotine on youth
Clinical Roundup
- Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma
- Phase III CheckMate -9ER meets primary PFS endpoint in RCC
- New targeted agent produces responses in trial with patients with uterine serous carcinoma
- RVD Therapy shows substantial benefit in large myeloma study
- Cue Biopharma and Merck to evaluate CUE-101 + Keytruda in head and neck indication
Drugs & Targets
- FDA approves Tukysa in breast cancer indication
- FDA grants accelerated approval for Trodelvy in previously-treated metastatic TNBC
- FDA approves first targeted treatment for patients with cholangiocarcinoma
- FDA approves Imbruvica in CLL/SLL indication
- FDA approves Keytruda companion diagnostic

Page 11 of 116« First «...7 8 9 101112 13 14 15 16...30 40 50 60 70 80 90 100 110...»Last »